AOD-9604
Modified C-terminal fragment of human growth hormone studied for selective fat-cell lipolysis without the blood sugar or anabolic side-effects of full-length HGH. Received FDA GRAS status for oral formulation.
What Research Shows
Studied for β3-adrenergic receptor-mediated lipolysis and lipogenesis inhibition in diet-induced obesity models, without IGF-1 receptor binding. Studies measure fat mass by DXA, serum free fatty acids, and glycerol release from adipose explants. Selective fat-targeting mechanism with favourable safety profile in published trials.
Pros & Cons
- +AOD-9604 received FDA GRAS (Generally Recognised As Safe) status for oral use — favourable regulatory safety signal
- +CJC-1295 DAC requires only once-weekly dosing due to its 6–8 day half-life — highly convenient vs. daily protocols
- +Ipamorelin is the most selective GH secretagogue available: no cortisol, prolactin, or ACTH elevation at standard doses
- +CJC-1295 has published Phase I and II human trial data with well-characterised GH/IGF-1 pharmacokinetics
- +AOD-9604 selectively activates β3 receptors in fat cells without binding IGF-1 receptors — no anabolic side-effects
- +Combination of CJC-1295 + Ipamorelin produces 2–5× greater GH pulse than either compound alone
- −All three compounds require subcutaneous injection — no oral route with established human bioavailability
- −CJC-1295 substantially raises IGF-1 levels: blood glucose monitoring is advisable, especially for pre-diabetic individuals
- −AOD-9604 Phase III obesity trials showed limited efficacy at the doses tested orally — systemic injectable effects differ
- −Body composition improvements require consistent use over weeks to months — not a rapid intervention
- −Canadian availability is currently limited: only Particle Peptides consistently stocks all three in 2026
- −GH elevation during sleep can disrupt sleep architecture if dosed too close to bedtime
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary significantly.
GH serum elevation from CJC-1295 is detectable within 24 hours of first injection. Measurable body composition changes (DXA-measured fat mass reduction) in animal models require 4–6 weeks at minimum. Human self-researcher timelines are typically 8–12 weeks before significant changes in body composition become visible.
What People Research This For
Practical Questions
When is the best time to inject CJC-1295 + Ipamorelin?
Published animal studies and the CJC-1295 Phase I trial use a single weekly or biweekly SC injection without time-of-day specification. The self-research community commonly doses Ipamorelin immediately before sleep, as natural GH secretion is highest during slow-wave sleep — and GH secretagogues amplify this natural pulse. CJC-1295 DAC is typically injected once weekly at any time due to its extended half-life.
Is AOD-9604 a safer alternative to HGH for fat loss?
AOD-9604 was specifically engineered to retain the lipolytic (fat-burning) activity of growth hormone while eliminating its anabolic and diabetogenic effects. It does not bind the IGF-1 receptor and does not significantly alter blood glucose in published studies — key advantages over full-length HGH. However, "safer" must be understood in context: AOD-9604 has no long-term human safety data for injectable use, and the FDA GRAS designation applies to an oral formulation, not injectable.
Do I need to cycle off CJC-1295 and Ipamorelin?
Published human trials ran for 4–6 weeks without tolerance or desensitisation issues. The self-research community commonly uses 3-month on / 1-month off cycles, though this is convention rather than evidence-based protocol. There is theoretical concern that chronic GHRH receptor stimulation could cause pituitary desensitisation over very long periods — a risk that has not been systematically studied at research peptide doses.
Where to Buy AOD-9604 in Canada
3 Canada-accessible vendors currently stock AOD-9604, including 1 with domestic warehouse. Compare prices and availability below.